AMRN

Vascepa

Cardiovascular disease (triglyceride lowering)

Quarterly Sales (Approved)

Exp Date

July 31, 2020 (Est)

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Quarterly Sales for Vascepa used to lower cholesterol (FDA-approved drug) 


WHAT IS THE CATALYST EVENT?

  • Quarterly Sales


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • July 31, 2020 (Est)


PRIOR DATA 


PRESS RELEASES

MECHANISM OF ACTION/RATIONALE

  • Studies suggest that EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity.

  • FDA Drug Label (slide 5, section 12.1)

Updated by HC

AMRN, Vascepa, Vascepa Revenue, MACE

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

Jackpot...

BINGO #winner #ZGNX #AMRN #AIMT...

Experienced biotech patent att...

Check out my 20 minute video about the ongoing AMRN ANDA appeal. It includes valuable information include key dates in the litigation as well as the #1 misconception of biotech invenstors regarding th...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon